Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
By
- AMS
posted
Apr 21, 2020 12:02 PM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials
- AMS
Added Oct 21, 2020
Blog Entry
Merz Aesthetics Announces Positive Results From Study Demonstrating Efficacy and Safety of Belotero Balance
The Aesthetic GUIDE
Added Jun 14, 2023
Blog Entry
Merz Aesthetics Announces Positive Phase 3 Data Demonstrating Efficacy and Safety of Xeomin In Treating Upper Facial Lines
The Aesthetic GUIDE
Added Jun 14, 2023
Blog Entry
Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events
- AMS
Added Apr 22, 2020
Blog Entry
New evidence-based resources to guide treatment of plaque psoriasis
- AMS
Added Sep 08, 2021
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic